Business 4 min read By Alice Ashford
Boston Scientific warns cyberattack will hit 2026 sales and profit
Boston Scientific has told investors it is unlikely to meet its 2026 sales and profit forecasts after a cyberattack disrupted operations, with the company now assessing the financial damage from the breach.
Boston Scientific has warned investors that it will probably miss its 2026 sales and profit targets because of disruption caused by a cyberattack, marking one of the most significant corporate casualties of the recent wave of security breaches in the medical technology sector.
The US-based medical devices maker said the attack had interfered with parts of its business operations, and that the resulting disruption would weigh on revenue and earnings into next year. The company stopped short of providing a revised full-year outlook, saying it was still quantifying the impact, but acknowledged that its previous guidance was no longer achievable.
The warning underscores how vulnerable healthcare manufacturers have become to cyber threats, with attackers increasingly targeting companies whose products are critical to hospital and clinical workflows. Boston Scientific, which makes pacemakers, heart monitors and other implantable devices, is among the largest players in the sector, and any prolonged operational disruption carries consequences for hospitals and patients who depend on its supply chain.
The company did not disclose the nature of the attack, who was behind it, or which specific systems had been compromised. It said it had contained the breach and was working to restore normal operations, but that the recovery process would take time and would have a measurable effect on financial performance.
News of the profit warning sent the company's shares lower in after-hours trading, reflecting investor concern that the financial fallout could extend beyond the current quarter. Analysts noted that Boston Scientific had been enjoying strong momentum in its core cardiology and neuromodulation businesses, making the timing of the cyberattack particularly painful.
The incident adds to a growing list of cyberattacks that have disrupted major healthcare organisations in recent years. Hospitals, pharmaceutical companies and medical device manufacturers have all been targeted, with attackers often seeking ransom payments or simply causing chaos. Regulators on both sides of the Atlantic have been pressing companies in the sector to harden their cyber defences, warning that patient safety and supply chain resilience are at stake.
For Boston Scientific, the immediate priority is operational recovery. The company said it was cooperating with law enforcement and had engaged external cybersecurity experts to investigate the breach and prevent further intrusion. It also said it was communicating with customers and regulators to manage the impact on product availability.
The profit warning is a reminder that cyber risk has become a mainstream financial issue for listed companies, capable of derailing carefully constructed annual forecasts. Investors have grown accustomed to hearing about data breaches, but the Boston Scientific case shows that attacks can also directly hit the top and bottom lines of industrial businesses whose operations depend on continuous, secure digital systems.
The company said it would provide a more detailed update on the financial impact once its assessment was complete. Until then, shareholders and analysts are left to weigh the possibility that the disruption could spill into 2026, a year for which Boston Scientific had previously set ambitious growth targets.
